VENTILATORS may be causing the lung damage, not the virus
A NYC physician named Cameron Kyle-Sidell has posted two videos on YouTube, pleading for health practitioners to recognize that COVID-19 is not a pneumonia-like disease at all. It’s an oxygen deprivation condition, and the use of ventilators may be doing more harm than good with some patients. The ventilators themselves, due to the high-pressure methods they are running, may be damaging the lungs and leading to widespread harm of patients.
Dr. Cameron Kyle-Sidell describes himself as an “ER and critical care doctor” for NYC. “In these nine days I have seen things I have never seen before,” he says. Before publishing his video, we confirmed that Dr. Kyle-Sidell is an emergency medicine physician in Brooklyn and is affiliated with the Maimonides Medical Center located in Brooklyn.
In his video (see below), he goes on to warn the world that the entire approach to treating COVID-19 may be incorrect, and that the disease is something completely different from what the dogmatic medical establishment is claiming.
More
DelMarVa's Premier Source for News, Opinion, Analysis, and Human Interest Contact Publisher Joe Albero at alberobutzo@wmconnect.com or 410-430-5349
Dropping oxygen levels because of full lungs is why they’re on respirators... who is this quack
ReplyDeleteI suspect I had this over a year ago. Out of work for a week high fever shallow lungs. Never been so sick. Thank goodness I had a nebulizer and Albuteral. This is a not so recent development.
ReplyDeleteYou can believe any conspiracy that fits your beliefs and philosophy. When your drowning with scared lungs full of Mucus you may want to believe in Science in your final ventilated hours and hope you get a face time call home to your loved ones.
ReplyDeleteNo doubt. Most in the medical community are clueless and still doing things from the 1920's
ReplyDeleteThere are only truly a handful of doctors here that have a clue.
April 6, 2020 at 5:31 PM I had it in January and the albuterol and nebulizer did nothing. Didn't put a dent in it.
ReplyDeleteIf it were that simple, people would not be dying from it and would be prescribed an inhaler or breathing treatments.
You did not have it, if you are touting relief with albuterol.
You are just as bad as the doctors around here. Quack quack.
ECMO treatment?
DeleteDoctors in Italy noted patient could breath better laying on their stomach.
Novartis unveils plans to begin trial with Jakavi in severe COVID-19 patients
Deleterdharma@digitalinsightresearch.in rdharma@digitalinsightresearch.in
3 days ago
Novartis has unveiled plans to start trial with Jakavi in severe COVID-19 patients. (Credit: PIRO4D from Pixabay.)
Novartis will work with Incyte to begin a phase III clinical study to assess the application of Jakavi to treat cytokine storm, a type of severe immune overreaction that may cause respiratory complications in patients with COVID-19.
The Swiss firm said that its decision is based on pre-clinical evidence and preliminary reports from independent studies, as well as supported by comprehensive data on the safety and efficacy of Jakavi in conditions such as acute graft versus host disease and myeloproliferative neoplasms.
The proposed study will evaluate Jakavi in combination with standard of care (SoC) therapy compared against SoC therapy alone in patients with severe COVID-19 pneumonia due to SARS-CoV-2 infection.
Novartis has also announced the creation of an international compassionate use programme for eligible patients, subject to local regulations. The ruxolitinib access requests are monitored by Incyte in the US.
Jakavi, an oral inhibitor of the JAK 1 and JAK 2 tyrosine kinases, secured approval from the European Commission (EC) to treat adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea.
It is also approved to treat disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (MF), post-polycythemia vera MF or post-essential thrombocythemia MF.
Jakavi secured approval in 101 countries for patients with MF, as well as in over 75 countries for patients with PV.
Novartis secured a licence for ruxolitinib from Incyte to develop and commercialise in selected indications outside the US.
In the US, Incyte commercialised ruxolitinib as Jakafi for patients with PV who have had an inadequate response to or are intolerant of hydroxyurea, for patients with intermediate or high-risk MF, and steroid-refractory acute GvHD in adult and pediatric patients 12 years and older.
Novartis global drug development head and chief medical officer John Tsai said: “The potential that Jakavi could lead to faster recovery times for COVID-19 patients with fewer requiring intensive care and mechanical ventilation is encouraging and absolutely merits further investigation.
“We now are moving rapidly to finalize the study plan and then to enrol eligible patients, as well as put in place a process to provide access for patients unable to participate in the trial.”
In March this year, Novartis and a consortium of life sciences companies have collaborated with Bill & Melinda Gates Foundation (BMGF) to advance the development, manufacture and delivery of vaccines, diagnostics and treatments for COVID-19, the disease resulted due to the novel coronavirus SARS-CoV-2.
Did you self quarantine 8:36?
Delete